Insights

Innovative Diagnostic Solution AboGen's development of saliva-based diagnostic and research applications presents a disruptive alternative to traditional blood-based testing, offering a less invasive, more patient-friendly option that could open doors to new markets such as primary care, telehealth, and remote diagnostics.

Strategic Collaborations The company's recent partnerships with prominent pharmaceutical firms for mRNA vaccine development indicate strong industry recognition and potential for expanding into additional biotech and pharma collaborations, increasing the range of diagnostic and therapeutic offerings.

Vaccine Development Focus With ongoing projects in COVID-19, dengue, TB, meningitis, and HPV vaccines, AboGen is positioned to serve global health markets seeking innovative vaccine solutions, providing opportunities for sales of related biotech reagents, consumables, and equipment.

Significant Funding and Growth The substantial $700M Series C funding highlights investor confidence and potential for rapid expansion, allowing for increased sales efforts in biotech research tools, clinical diagnostics, and collaborative R&D services.

Tech-Enabled Research Platform AboGen's utilization of advanced digital tools and cloud-based infrastructure enables scalable, data-driven research workflows, creating opportunities to sell complementary software, data analytics, and IT solutions to other biotech players seeking to modernize their research processes.

Similar companies to Abogen, Inc.

Abogen, Inc. Tech Stack

Abogen, Inc. uses 8 technology products and services including Google Workspace, Font Awesome, React, and more. Explore Abogen, Inc.'s tech stack below.

Google Workspace
Email
Font Awesome
Font Scripts
React
Javascript Frameworks
Chart.js
Javascript Graphics
jQuery UI
Javascript Libraries
Amazon ALB
Load Balancers
PHP
Programming Languages
GoDaddy
Web Hosting

Media & News

Abogen, Inc.'s Email Address Formats

Abogen, Inc. uses at least 1 format(s):

Abogen, Inc. Email Formats	Example	Percentage
FLast@abogen.com	JDoe@abogen.com	44%
F.Last@abogen.com	J.Doe@abogen.com	6%
FLast@abogen.com	JDoe@abogen.com	44%
F.Last@abogen.com	J.Doe@abogen.com	6%

Frequently Asked Questions

Where is Abogen, Inc.'s headquarters located?

Abogen, Inc.'s main headquarters is located at 474 Congress St., Portland, ME 04101, US. The company has employees across 2 continents, including North AmericaAsia.

What is Abogen, Inc.'s phone number?

You can contact Abogen, Inc.'s main corporate office by phone at

+1-207-939-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Abogen, Inc.'s official website and social media links?

Abogen, Inc.'s official website is abogen.com and has social profiles on LinkedIn.

What is Abogen, Inc.'s SIC code NAICS code?

Abogen, Inc.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Abogen, Inc. have currently?

As of October 2025, Abogen, Inc. has approximately 3 employees across 2 continents, including North AmericaAsia. Key team members include Chief Innovation Officer: M. J.Chief Business Officer- Acting: M. S.President And Co-Founder: Y. B.. Explore Abogen, Inc.'s employee directory with LeadIQ.

What industry does Abogen, Inc. belong to?

Abogen, Inc. operates in the Biotechnology Research industry.

What technology does Abogen, Inc. use?

Abogen, Inc.'s tech stack includes Google WorkspaceFont AwesomeReactChart.jsjQuery UIAmazon ALBPHPGoDaddy.

What is Abogen, Inc.'s email format?

Abogen, Inc.'s email format typically follows the pattern of FLast@abogen.com. Find more Abogen, Inc. email formats with LeadIQ.

How much funding has Abogen, Inc. raised to date?

As of October 2025, Abogen, Inc. has raised $700M in funding. .

When was Abogen, Inc. founded?

Abogen, Inc. was founded in 2012.

Abogen, Inc.

Biotechnology ResearchUnited States2-10 Employees

At AboGen, we believe that drawing large volumes of blood using invasive needles for research and diagnostic purposes does not fit with the 21st century.
Founded in 2012, AboGen Inc. is the world's first company to show, through various independent 3rd party validators, that its technology can allow for the use of saliva, instead of blood, for various cell based research and diagnostic applications, including serological and genetic. 
We do not plan on replacing blood completely but we do plan on elevating saliva, as an alternative to blood for various cell based diagnostic applications, ABOve and beyond GENetic applications.

Company Overview

Headquarters: 474 Congress St., Portland, ME 04101, US
Phone number: +1-207-939-****
Website: abogen.com
SIC Code: 8733 - Noncommercial Research Organizations
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded: 2012
Employees: 2-10